Prostate Cancer Misdiagnosis Elimination Act of 2017

Bill 115 hr 2557, also known as the Prostate Cancer Misdiagnosis Elimination Act of 2017, aims to address the issue of misdiagnosis of prostate cancer in the United States. The bill was introduced in the House of Representatives in 2017 and has since been under consideration by Congress.

The main purpose of the bill is to improve the accuracy of prostate cancer diagnoses by implementing new guidelines and standards for testing and diagnosis. The bill calls for increased training and education for healthcare providers on the latest diagnostic techniques and technologies for detecting prostate cancer.

Additionally, the bill seeks to establish a national registry for tracking cases of misdiagnosis of prostate cancer. This registry would help identify trends and patterns in misdiagnosis and allow for better understanding of the factors contributing to inaccurate diagnoses. Furthermore, the bill includes provisions for increased research funding for studying prostate cancer and developing new diagnostic tools and treatments. This research funding would help advance the field of prostate cancer detection and treatment, ultimately leading to better outcomes for patients. Overall, the Prostate Cancer Misdiagnosis Elimination Act of 2017 aims to improve the accuracy of prostate cancer diagnoses, reduce instances of misdiagnosis, and ultimately improve the quality of care for patients with prostate cancer.